0 CHECKOUT

PRODUCT FILTERS

REGION

46
4
3
3
1

COUNTRY

3

PRICE

7
8
10
60

PUBLISHED

0
3
8
60

PRODUCT TYPE

59
1

Prostate Cancer

The second leading cause of new cancer cases in men worldwide with over two million sufferers in the US alone, prostate cancer is typically a disease that affects older men and is thus on the increase as global life expectancies continue to rise. It is also one of the largest sectors of the pharmaceutical oncology industry. Expertly formulated reports in this section will help you to formulate effective market strategies by answering key questions such as who are the main and key niche players, what are the new drugs and therapies (including vaccines and therapeutic antibodies) in the pipeline, and what are the latest areas of pharmaceutical R&D. Manufacturers will find multiple report options to assist them in assessing competition and market opportunities. Show Less Read more

60 Products

World Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics - Market Opportunity and Forecast, 2014 - 2020

Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining...

Published:  July 2015
Price:  From

Global Prostate Cancer Devices Market 2015-2019

About Prostate Cancer Prostate cancer is one of the most common cancer in men. It occurs in the prostate gland, a small walnut-shaped gland. The primary function of the prostate gland is to produce...

Published:  June 2015
Price:  From

Global Prostate Cancer Drugs Market 2014-2018

About Prostate Cancer Prostate cancer initiates in the prostate, which is an exocrine gland present in the male reproductive system. The main function of the prostate is to make fluid for semen. The...

Published:  November 2014
Price:  From

Prostate Cancer Pipeline Highlights - 2015

The latest report Prostate Cancer Pipeline Highlights – 2015 Update, provides most up-to-date information on key pipeline molecules in the global Prostate Cancer market. It covers emerging therapies...

Published:  July 2015
Price:  From

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2023 Summary Prostate cancer is the second most common cancer in men worldwide, after skin cancer. It accounts for 15% of...

Published:  April 2015
Price:  From

Prostate Cancer Drug Pathway Analyzer 2015

Extra value: One year of free online updates included with this product There are today at least 413 targeted molecular therapies known to affect more than 249 specific intracellular signaling pathways...

Published:  January 2015
Price:  From

Global Prostate Cancer Epidemiology and Patient Flow Analysis - 2015

The author announced the results of its Prostate Cancer patient population study in a new report ‘Global Prostate Cancer Epidemiology and Patient Flow Analysis - 2015’. The report provides insights...

Published:  January 2015
Price:  From

Frontier Pharma: Prostate Cancer - Identifying and Commercializing First-in-Class Innovation

Summary: Exceptionally Large and Innovative Pipeline. The prostate cancer pipeline is among the largest in the pharmaceutical industry with 484 products in active development across all stages....

Published:  November 2014
Price:  From

Analytical Tool - Prostate Cancer

"Analytical Tool - Prostate Cancer" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in prostate cancer R&D and business development. It is at the same...

Published:  March 2014
Price: 

US Prostate Cancer Drug Pipeline Analysis

Prostate cancer has emerged as one of the most commonly diagnosed cancer among men in the US According to the American Cancer Society, there were close to 242,000 new cases of prostate cancer in the...

Published:  October 2013
Price:  From

Triple Analysis: Leukemia, Melanoma and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Leukemia, Melanoma and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria in...

Published:  June 2013
Price:  From

Triple Analysis: Melanoma, Prostate Cancer and Apoptosis

This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated...

Published:  June 2013
Price:  From

Triple Analysis: Colorectal Cancer, Melanoma and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Melanoma and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria...

Published:  June 2013
Price:  From

Triple Analysis: Lung Cancer, Melanoma and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Melanoma and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria...

Published:  June 2013
Price:  From

Triple Analysis: Melanoma, Pancreatic Cancer and Prostate Cancer

This triple analysis focuses on cancer drug development strategies in Melanoma, Pancreatic Cancer and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria...

Published:  June 2013
Price:  From

Triple Analysis: Melanoma, Prostate Cancer and Angiogenesis

This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated...

Published:  June 2013
Price:  From

Triple Analysis: Melanoma, Prostate Cancer and Antibodies

This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the compound strategy of Antibodies. Each of these three individual parts is evaluated...

Published:  June 2013
Price:  From

KOL Insight: Prostate Cancer: Competition intensifies in race to the top

The Prostate Cancer market has seen a number of progressive changes in recent years The launches of Johnson & Johnson's Zytiga (abiraterone acetate) and Medivation/Astellas's Xtandi (enzalutamide) has...

Published:  June 2013
Price:  From

Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top

Charting the Future Prostate Cancer Market Landscape The prostate cancer market has experienced substantial changes in the last five years with patent expiries of key compounds and approvals of new...

Published:  June 2013
Price:  From
Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top - Product Thumbnail Image

Triple Analysis: Prostate Cancer, Apoptosis and Peptides

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides)....

Published:  January 2013
Price:  From
Loading Indicator

Our Clients